



TFN

PATENT
ATTORNEY DOCKET NO. 50248/005002

Certificate of Mailing: Date of Deposit: March 22, 2007

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sarah Wilcox

Printed name of person mailing correspondence

Sarah Wilcox

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Burton et al.	Confirmation No.:	Not yet assigned
Serial No.:	10/589,700	Art Unit:	Not yet assigned
Filed:	August 17, 2006	Examiner:	Not yet assigned
Customer No.:	21559		
Title:	TOPICAL FORMULATIONS FOR THE TREATMENT OF SKIN CONDITIONS		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

/Thor Nielsen/

03/10/2011

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./


This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

March 21, 2007



Kristina Bieker-Brady, Ph.D.
Reg. No. 39,109

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. Serial No. Applicant Filing Date Group IDS Filed	50248/005002 10/589,700 Burton et al. August 17, 2006 Not yet assigned March 22, 2007
--	--	---	--

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	4,642,318	Feb. 10, 1987	Wolff
	4,889,847	Dec. 26, 1989	Kligman et al.
	5,475,006	Dec. 12, 1995	Burton et al.
	5,646,186	Jul. 8, 1997	Wang et al.
	5,719,195	Feb. 17, 1998	Braiman
	5,874,093	Feb. 23, 1999	Eliasz and Gonen
	5,965,616	Oct. 12, 1999	Wang and Wisniewski
	5,998,395	Dec. 7, 1999	Kligman
	6,008,254	Dec. 28, 1999	Kligman et al.
	6,228,887	May 8, 2001	Kligman and Kligman
	6,544,532	Apr. 8, 2003	Jager-Lezer and Lorient
	7,132,458	Nov. 7, 2006	Burton et al.
	08/527,039	Sept. 12, 1995	Burton et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	CA 2,171,625 A1	Feb. 22, 1996	C.I.P.O.	
	CA 2,221,122 A1	May 15, 1998	C.I.P.O.	
	WO 93/15740 A1	Aug. 19, 1993	W.I.P.O.	
	WO 96/05160 A1	Feb. 22, 1996	W.I.P.O.	
	WO 96/34601 A1	Nov. 7, 1996	W.I.P.O.	
EXAMINER /Thor Nielsen/			DATE CONSIDERED 03/10/2011	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to the applicant.				

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./

Sheet 2 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50248/005002
<p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> <p>(37 C.F.R. § 1.98(b))</p>		Serial No.	10/589,700
		Applicant	Burton et al.
		Filing Date	August 17, 2006
		Group	Not yet assigned
		IDS Filed	March 22, 2007

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Burton and Ingold, "β-Carotene: An Unusual Type of Lipid Antioxidant" <i>Science</i> 224:569-573 (1984).
	Morganli et al., "Protective Effects of Oral Antioxidants on Skin and Eye Function," <i>SKINmed</i> . 3:310-316 (2004).

EXAMINER /Thor Nielsen/	DATE CONSIDERED 03/10/2011
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to the applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./